Skip to main content
. Author manuscript; available in PMC: 2010 Jul 1.
Published in final edited form as: Toxicol Appl Pharmacol. 2009 May 3;238(1):90–99. doi: 10.1016/j.taap.2009.04.019

Table 2.

Parameter estimates from non-compartmental analysis.

Parameters TCEa TCAb DCAb DCVGb DCVCb
Cmax, μmol/l 1,647 388 0.088 0.0389 0.0028
Tmax, hr 0.43 8 0.5 0.5 8
T1/2, hr 3.32 7.92 7.41 3.00 4.15
AUClast, μmol/l ·hr 5,213 6,855 1.52 0.281 0.0212
AUC∞, μmol/l ·hr 5,260 12,612 3.02 0.283 0.0416
AUMC∞, μmol/l ·hr2 26,273 372,721 108 1.25 0.751
MRT∞, hr 5.00 29.6 35.2 4.41 18.1

Cmax, peak concentration (please note that background concentrations of TCA and DCA in mouse serum were subtracted from each time point prior to pharmacokinetic modeling); Tmax, peak time; T1/2, terminal half life; AUClast, area under the serum concentration-time curve between 0 and last observation; AUC∞, area under the serum concentration-time curve between 0 and ∞; AUMC, area under first-moment curve; MRT, mean residence time.

a

Experimental dose of 2000 mg/kg TCE in 0.0275 kg B6C3F1 mice in average (corresponding to 419 μmoles of TCE) (Abbas and Fisher, 1997).

b

Experimental dose of 2,140 mg/kg TCE onto 0.0357 kg B6C3F1 mice in average (corresponding to 581 μmoles of TCE) in the present study.